Antisense Oligonucleotide Splice Switching for Progranulin Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively increase progranulin expression and activity, which is crucial for treating neurological disorders such as frontotemporal dementia, and existing splice-switching agents like mesylphosphoramidate oligonucleotides do not show improved efficacy in altering the splicing pattern of progranulin.
Innovation Solution
Development of antisense oligonucleotides that are 8-40 nucleotides in length, complementary to splice regulation sites of progranulin pre-mRNA, incorporating methanesulfonyl phosphoramidate internucleotide linkages to enhance the splicing pattern, specifically up-regulating the Exon1-Exon2 progranulin splice variant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesylphosphoramidate oligonucleotides are used as splice-switching agents, then the therapeutic index and duration of effect are improved, but splice-switching efficacy is not significantly enhanced
Solution Approach 1:
The patent modifies the chemical structure of mesylphosphoramidate oligonucleotides by incorporating 2'-O-methoxyethyl (2'-MOE) modifications at specific positions within the oligonucleotide sequence. This structural parameter change enhances splice-switching efficacy while preserving the therapeutic index and duration of effect already provided by the mesylphosphoramidate backbone.
Solution Approach 2:
The invention creates a composite oligonucleotide structure combining mesylphosphoramidate internucleotide linkages with 2'-MOE modified nucleosides. This composite approach integrates the advantages of both components: the mesylphosphoramidate provides improved therapeutic index and duration, while the 2'-MOE modifications contribute to enhanced splice-switching efficacy.
2Object-affected harmful factors
If mesylphosphoramidate oligonucleotides are used, then immune stimulation and cytotoxicity are reduced, but splice-switching activity remains comparable to phosphorothioate controls
Solution Approach 1:
The patent introduces 2'-MOE modifications at specific positions (particularly in the central region) of the mesylphosphoramidate oligonucleotide sequence. This structural modification changes the physical and chemical parameters of the oligonucleotide, enhancing its ability to induce splice switching while maintaining the reduced immune stimulation and cytotoxicity characteristics of the mesylphosphoramidate backbone.
3Reliability
If antisense oligonucleotides target splice regulation sites to up-regulate Exon1-Exon2 variant, then progranulin protein expression increases, but the complexity of oligonucleotide design and synthesis increases
Solution Approach 1:
The patent optimizes the length and sequence parameters of the antisense oligonucleotide to target specific splice regulation sites in progranulin pre-mRNA. By carefully selecting the target sequence and optimizing oligonucleotide length (typically 15-30 nucleotides), the patent achieves effective splice switching to up-regulate the Exon1-Exon2 variant while managing design complexity through focused target selection.
Solution Approach 2:
The mesylphosphoramidate linkage acts as an intermediary chemical structure that facilitates the interaction between the oligonucleotide and its target pre-mRNA. This specialized linkage provides both structural stability and biological activity, enabling the oligonucleotide to effectively modulate splicing without requiring overly complex design features.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides significantly increase the expression of the Exon1-Exon2 progranulin splice variant, potentially restoring progranulin protein levels and addressing neurological disorders.
Implementation Method 1
antisense oligonucleotides which alter the splicing pattern of progranulin... comprises a contiguous nucleotide sequence which is complementary to a splice regulation site of progranulin pre-mRNA
Data Source
AI summary
Antisense oligonucleotides for altering the splicing pattern of progranulin, and their use in the treatment of neurological disorders. The antisense oligonucleotides are modified to better increase up-regulation or expression restoration of the Exon1-Exon2 progranulin splice variant in cells.